VivoSim Labs, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
VivoSim Labs, Inc. (VIVS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $91.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- VivoSim Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $91.00K, a 16.67% increase year-over-year.
- VivoSim Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $67.00K, a 48.46% decline year-over-year.
- VivoSim Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $72.00K, a 53.55% decline year-over-year.
- VivoSim Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $78.00K, a 50.00% decline year-over-year.
- VivoSim Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2026 was $303.00K, a 43.05% decline from fiscal 2025.
- VivoSim Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $532.00K, a 64.72% decline from fiscal 2024.
- VivoSim Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.51M, a 36.56% decline from fiscal 2023.
- VivoSim Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.38M, a 5.36% increase from fiscal 2022.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $91.00K 10-Q · filed 2026-08-12 | ||||
| 2026-03-31 | $303.00K 10-K · filed 2026-07-14 | ||||
| 2025-12-31 | $67.00K 10-Q · filed 2026-02-11 | $139.00K derived: sum of 2 quarters · filed 2026-02-11 | $217.00K derived: sum of 3 quarters · filed 2026-08-12 | ||
| 2025-09-30 | $72.00K 10-Q · filed 2026-02-11 | $150.00K derived: sum of 2 quarters · filed 2026-08-12 | |||
| 2025-06-30 | $78.00K 10-Q · filed 2026-08-12 | ||||
| 2025-03-31 | $532.00K 10-K · filed 2026-07-14 | ||||
| 2024-12-31 | $130.00K 10-Q · filed 2026-02-11 | $285.00K derived: sum of 2 quarters · filed 2026-02-11 | $441.00K derived: sum of 3 quarters · filed 2026-02-11 | ||
| 2024-09-30 | $155.00K 10-Q · filed 2026-02-11 | $311.00K derived: sum of 2 quarters · filed 2026-02-11 | |||
| 2024-06-30 | $156.00K 10-Q · filed 2026-02-11 | ||||
| 2024-03-31 | $1.51M 10-K · filed 2025-06-05 | ||||
| 2023-12-31 | $157.00K 10-Q · filed 2025-02-19 | $832.00K derived: sum of 2 quarters · filed 2025-02-19 | $1.31M derived: sum of 3 quarters · filed 2025-02-19 | ||
| 2023-09-30 | $675.00K 10-Q · filed 2025-02-19 | $1.15M derived: sum of 2 quarters · filed 2025-02-19 | |||
| 2023-06-30 | $475.00K 10-Q · filed 2025-02-19 | ||||
| 2023-03-31 | $2.38M 10-K · filed 2024-05-31 | ||||
| 2022-12-31 | $544.00K 10-Q · filed 2024-02-08 | $1.22M derived: sum of 2 quarters · filed 2024-02-08 | $1.88M derived: sum of 3 quarters · filed 2024-02-08 | ||
| 2022-09-30 | $673.00K 10-Q · filed 2024-02-08 | $1.33M derived: sum of 2 quarters · filed 2024-02-08 | |||
| 2022-06-30 | $660.00K 10-Q · filed 2024-02-08 | ||||
| 2022-03-31 | $2.26M 10-K · filed 2023-07-14 | ||||
| 2021-12-31 | $588.00K 10-Q · filed 2023-02-09 | $1.01M derived: sum of 2 quarters · filed 2023-02-09 | $1.43M derived: sum of 3 quarters · filed 2023-02-09 | ||
| 2021-09-30 | $426.00K 10-Q · filed 2023-02-09 | $841.00K derived: sum of 2 quarters · filed 2023-02-09 | |||
| 2021-06-30 | $415.00K 10-Q · filed 2023-02-09 | ||||
| 2021-03-31 | $5.56M 10-K · filed 2022-06-10 | ||||
| 2020-12-31 | $206.00K 10-Q · filed 2022-02-14 | $4.34M derived: sum of 2 quarters · filed 2022-02-14 | $5.27M derived: sum of 3 quarters · filed 2022-02-14 | ||
| 2020-09-30 | $4.14M 10-Q · filed 2022-02-14 | $5.06M derived: sum of 2 quarters · filed 2022-02-14 | |||
| 2020-06-30 | $925.00K 10-Q · filed 2022-02-14 | ||||
| 2020-03-31 | $4.11M 10-K · filed 2021-06-15 | ||||
| 2019-12-31 | $1.25M 10-Q · filed 2021-02-08 | $2.49M derived: sum of 2 quarters · filed 2021-02-08 | $3.71M derived: sum of 3 quarters · filed 2021-02-08 | $4.99M derived: sum of 4 quarters · filed 2021-02-08 | |
| 2019-09-30 | $1.24M 10-Q · filed 2021-02-08 | $2.46M derived: sum of 2 quarters · filed 2021-02-08 | $3.74M derived: sum of 3 quarters · filed 2021-02-08 | $5.10M derived: sum of 4 quarters · filed 2021-02-08 | |
| 2019-06-30 | $1.22M 10-Q · filed 2021-02-08 | $2.50M derived: sum of 2 quarters · filed 2021-02-08 | $3.86M derived: sum of 3 quarters · filed 2021-02-08 | $5.13M derived: sum of 4 quarters · filed 2021-02-08 | |
| 2019-03-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-28 | $2.64M derived: sum of 2 quarters · filed 2020-05-28 | $3.91M derived: sum of 3 quarters · filed 2020-05-28 | $5.19M 10-K · filed 2020-05-28 | |
| 2018-12-31 | $1.36M 10-Q · filed 2020-02-10 | $2.63M derived: sum of 2 quarters · filed 2020-02-10 | $3.91M 10-Q · filed 2019-02-07 | ||
| 2018-09-30 | $1.27M 10-Q · filed 2020-02-10 | $2.55M derived: sum of 2 quarters · filed 2020-02-10 | |||
| 2018-06-30 | $1.28M 10-Q · filed 2020-02-10 | ||||
| 2018-03-31 | $6.90M 10-K · filed 2019-06-03 | ||||
| 2017-03-31 | $7.39M 10-K · filed 2018-05-31 | ||||
| 2016-03-31 | $8.56M 10-K · filed 2018-05-31 | ||||
| 2015-03-31 | $7.02M 10-K · filed 2017-06-07 | ||||
| 2014-03-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2016-06-09 | $2.51M derived: sum of 2 quarters · filed 2016-06-09 | $3.80M derived: sum of 3 quarters · filed 2016-06-09 | $4.60M 10-K · filed 2016-06-09 | |
| 2013-12-31 | $752.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-02-06 | $2.04M derived: sum of 2 quarters · filed 2014-02-06 | $2.84M 10-Q · filed 2014-02-06 | $3.69M derived: sum of 4 quarters · filed 2015-06-09 | |
| 2013-09-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-11-08 | $2.09M 10-Q · filed 2013-11-08 | $2.94M derived: sum of 3 quarters · filed 2015-06-09 | $3.09M derived: sum of 4 quarters · filed 2015-06-09 | |
| 2013-06-30 | $802.00K 10-Q · filed 2013-08-09 | $1.65M derived: sum of 2 quarters · filed 2015-06-09 | $1.80M derived: sum of 3 quarters · filed 2015-06-09 | $3.04M derived: sum of 4 quarters · filed 2015-06-09 | |
| 2013-03-31 | $848.00K 10-K · filed 2015-06-09 | $998.47K derived: sum of 2 quarters · filed 2015-06-09 | $2.24M derived: sum of 3 quarters · filed 2015-06-09 | $2.28M derived: sum of 4 quarters · filed 2015-06-09 | |
| 2012-12-31 | $150.47K derived: 10-K 12 month − 10-Q 9 month · filed 2015-06-09 | $1.39M derived: sum of 2 quarters · filed 2015-06-09 | $1.43M derived: sum of 3 quarters · filed 2015-06-09 | $1.44M 10-K · filed 2015-06-09 | |
| 2012-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14 | $1.28M derived: sum of 2 quarters · filed 2012-11-14 | $1.28M 10-Q · filed 2012-11-14 | ||
| 2012-06-30 | $38.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | $42.64K 10-Q · filed 2012-08-14 | |||
| 2012-03-31 | $3.87K 10-Q · filed 2012-05-15 | ||||
| 2011-12-31 | $9.00K 10-K · filed 2014-06-10 | $9.02K 10-Q · filed 2012-05-15 | |||
| 2010-12-31 | $4.00K 10-K · filed 2014-06-10 | $3.86K 10-Q · filed 2012-05-15 | |||
| 2009-12-31 | $2.00K 10-K · filed 2014-06-10 | $2.34K 10-Q · filed 2012-05-15 | |||
| 2008-12-31 | $2.00K 10-K · filed 2014-06-10 | $1.74K 10-Q · filed 2012-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |